

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

RESUMPTION OF TRADING

Reference is made to the announcement (“**Announcement**”) of CanSino Biologics Inc. (the “**Company**”) dated February 10, 2021 in relation to inside information. Having made such enquiry with respect to the Company as is reasonable in the circumstance, the Company confirms that save as disclosed in the Announcement, the Company is not aware of any information which must be announced to avoid a false market in the Company’s securities or of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

At the request of the Company, trading in the H shares (the “**Shares**”) of the Company has been halted with effect from 3:23 p.m. on February 10, 2021 pending release of the Announcement. Application has been made by the Company to The Stock Exchange of Hong Kong Limited for the resumption of trading in the Shares from 9:00 a.m. on February 11, 2021. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the Shares.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 10, 2021

As at the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.